• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

对耐药和敏感临床分离株中吡嗪酰胺酶和DNA旋转酶蛋白质结构的见解。 （原文中“of.”后面似乎缺少具体内容）

Insights into Pyrazinamidase and DNA Gyrase Protein Structures in Resistant and Susceptible Clinical Isolates of .

作者信息

Ahmadi Azam, Nazari Raziyeh, Arjomandzadegan Mohammad, Zolfaghari Mohammad Reza, Vahidi Vahideh, Poolad Toktam, Kahbazi Manijeh, Sadrnia Maryam, Tousheh Mojtaba, Rafiee Pourya

机构信息

Department of Molecular Genetics, Tarbiat Modares University,; Infectious Diseases Research Center (IDRC), Arak University of Medical Sciences, Arak, Iran.

Department of Microbiology, Qom Branch, Islamic Azad University, Qom, Iran.

出版信息

Tanaffos. 2016;15(3):147-153.

PMID:28210279
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5304958/
Abstract

BACKGROUND

Mutations in and genes cause pyrazinamide (PZA) and fluroquinolone resistance in (). In the present study, structures of pyrazinamidase (PZase) and DNA gyrase proteins were studied in resistant and susceptible clinical isolates of

MATERIALS AND METHODS

Sixty clinical isolates of were used in this study. Polymerase chain reaction (PCR) amplification of and genes was accomplished on purified DNA. Sequence of the fragments was determined by an Applied BiosystemsTM apparatus. Bioinformatic analysis was performed by online software and three-dimensional (3D) structures of proteins was predicted using Molegro Virtual Docker (MVD) Modeler software.

RESULTS

Amplified 744 and 194 bp fragments of and genes, respectively were yielded suitable sequence results. Predicted 3D structures of proteins showed some differences between wild-type and mutant structures. Mutation in amino acid No.31 (T92C) caused an increase in distance from metal ion position to enzyme active site, but it was considered as a polymorphism. Docking results by MVD revealed a relationship in quinolone resistance-determining regions (QRDR) amino acids in interaction with antibiotic. T92C mutation in PZase from non-polar aliphatic amino acid Ile (ATC) to polar aliphatic amino acid threonine (ACC) was a polymorphism.

CONCLUSION

Structural changes in two important proteins related to drug resistance were proven in clinical isolates of .

摘要

背景

结核分枝杆菌中的pncA和gyrA基因发生突变会导致对吡嗪酰胺（PZA）和氟喹诺酮耐药。在本研究中，对结核分枝杆菌耐药和敏感临床分离株中的吡嗪酰胺酶（PZase）和DNA促旋酶蛋白结构进行了研究。

材料与方法

本研究使用了60株结核分枝杆菌临床分离株。在纯化的DNA上完成pncA和gyrA基因的聚合酶链反应（PCR）扩增。片段序列由Applied BiosystemsTM仪器测定。通过在线软件进行生物信息学分析，并使用Molegro Virtual Docker（MVD）建模软件预测蛋白质的三维（3D）结构。

结果

分别扩增出744 bp和194 bp的pncA和gyrA基因片段，获得了合适的序列结果。预测的蛋白质3D结构显示野生型和突变型结构之间存在一些差异。31号氨基酸（T92C）的突变导致金属离子位置到酶活性位点的距离增加，但被认为是一种多态性。MVD对接结果显示喹诺酮耐药决定区（QRDR）氨基酸与抗生素相互作用之间存在关系。PZase中T92C突变使非极性脂肪族氨基酸异亮氨酸（ATC）变为极性脂肪族氨基酸苏氨酸（ACC），这是一种多态性。

结论

在结核分枝杆菌临床分离株中证实了与耐药相关的两种重要蛋白质的结构变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e938/5304958/a914a675c433/Tanaffos-15-147-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e938/5304958/a9d196e99bd2/Tanaffos-15-147-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e938/5304958/117e53836537/Tanaffos-15-147-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e938/5304958/3762676a4b8a/Tanaffos-15-147-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e938/5304958/f7313fad5d76/Tanaffos-15-147-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e938/5304958/55f846c8fe25/Tanaffos-15-147-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e938/5304958/dc850050394b/Tanaffos-15-147-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e938/5304958/9a8345336db0/Tanaffos-15-147-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e938/5304958/a914a675c433/Tanaffos-15-147-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e938/5304958/a9d196e99bd2/Tanaffos-15-147-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e938/5304958/117e53836537/Tanaffos-15-147-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e938/5304958/3762676a4b8a/Tanaffos-15-147-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e938/5304958/f7313fad5d76/Tanaffos-15-147-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e938/5304958/55f846c8fe25/Tanaffos-15-147-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e938/5304958/dc850050394b/Tanaffos-15-147-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e938/5304958/9a8345336db0/Tanaffos-15-147-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e938/5304958/a914a675c433/Tanaffos-15-147-g008.jpg

相似文献

1
Insights into Pyrazinamidase and DNA Gyrase Protein Structures in Resistant and Susceptible Clinical Isolates of .对耐药和敏感临床分离株中吡嗪酰胺酶和DNA旋转酶蛋白质结构的见解。 （原文中“of.”后面似乎缺少具体内容）
Tanaffos. 2016;15(3):147-153.
2
Estimation of pyrazinamidase activity using a cell-free synthesis of pnca and its association with pyrazinamide susceptibility in .使用无细胞合成对硝基苯甲酸酯（pnca）估计吡嗪酰胺酶活性及其与吡嗪酰胺敏感性的关联。 （原文中“in.”后面似乎缺少内容）
Int J Mycobacteriol. 2018 Jan-Mar;7(1):16-25. doi: 10.4103/ijmy.ijmy_187_17.
3
[Characteristics of pncA gene in multidrug-resistant Mycobacterium tuberculosis isolates and its correlation with drug resistance to pyrazinamide].耐多药结核分枝杆菌分离株中pncA基因的特征及其与吡嗪酰胺耐药性的相关性
Zhonghua Yu Fang Yi Xue Za Zhi. 2012 May;46(5):436-9.
4
Genetic and phenotypic characterization of pyrazinamide-resistant mycobacterium tuberculosis complex isolates in Japan.日本耐吡嗪酰胺结核分枝杆菌复合群分离株的基因和表型特征
Diagn Microbiol Infect Dis. 2004 Feb;48(2):111-6. doi: 10.1016/j.diagmicrobio.2003.09.013.
5
Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan.巴基斯坦开伯尔-普赫图赫瓦省结核分枝杆菌分离株中吡嗪酰胺耐药性及 pncA 基因突变。
BMC Infect Dis. 2019 Feb 6;19(1):116. doi: 10.1186/s12879-019-3764-2.
6
Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis.pncA基因突变是结核分枝杆菌对吡嗪酰胺耐药的主要机制。
Tuber Lung Dis. 1997;78(2):117-22. doi: 10.1016/s0962-8479(98)80004-x.
7
Direct Detection of Pyrazinamide Resistance in Mycobacterium tuberculosis by Use of PCR Sequencing.利用 PCR 测序直接检测结核分枝杆菌中的吡嗪酰胺耐药性。
J Clin Microbiol. 2019 Jul 26;57(8). doi: 10.1128/JCM.00145-19. Print 2019 Aug.
8
Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis.耐吡嗪酰胺结核分枝杆菌中pncA基因突变的特征分析
Antimicrob Agents Chemother. 1997 Mar;41(3):540-3. doi: 10.1128/AAC.41.3.540.
9
Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Turkey.土耳其耐吡嗪酰胺结核分枝杆菌pncA基因突变特征分析
New Microbiol. 2009 Apr;32(2):153-8.
10
Mycobacterium tuberculosis isolates from Rio de Janeiro reveal unusually low correlation between pyrazinamide resistance and mutations in the pncA gene.里约热内卢分枝杆菌分离株显示吡嗪酰胺耐药性与 pncA 基因突变之间的相关性非常低。
Infect Genet Evol. 2013 Oct;19:1-6. doi: 10.1016/j.meegid.2013.06.008. Epub 2013 Jun 14.

本文引用的文献

1
Molecular detection of fluoroquinolone resistance-associated gyrA mutations in ofloxacin-resistant clinical isolates of Mycobacterium tuberculosis from Iran and Belarus.伊朗和白俄罗斯耐氧氟沙星结核分枝杆菌临床分离株中氟喹诺酮耐药相关gyrA基因突变的分子检测
Int J Mycobacteriol. 2016 Sep;5(3):299-305. doi: 10.1016/j.ijmyco.2016.07.004. Epub 2016 Aug 3.
2
Low rates of synonymous mutations in sequences of Mycobacterium tuberculosis GyrA and KatG genes.结核分枝杆菌 GyrA 和 KatG 基因序列中同义突变率低。
Tuberculosis (Edinb). 2012 Jul;92(4):333-44. doi: 10.1016/j.tube.2012.03.004. Epub 2012 Apr 21.
3
Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase.
结核分枝杆菌 DNA 回旋酶喹诺酮类耐药机制的结构研究
PLoS One. 2010 Aug 18;5(8):e12245. doi: 10.1371/journal.pone.0012245.
4
Sputum PCR-single-strand conformational polymorphism test for same-day detection of pyrazinamide resistance in tuberculosis patients.痰液聚合酶链反应-单链构象多态性检测用于同日检测结核病患者的吡嗪酰胺耐药性。
J Clin Microbiol. 2009 Sep;47(9):2937-43. doi: 10.1128/JCM.01594-08. Epub 2009 Jun 17.
5
Effect of pyrazinamidase activity on pyrazinamide resistance in Mycobacterium tuberculosis.吡嗪酰胺酶活性对结核分枝杆菌中吡嗪酰胺耐药性的影响。
Tuberculosis (Edinb). 2009 Mar;89(2):109-13. doi: 10.1016/j.tube.2009.01.004. Epub 2009 Feb 26.
6
Multidrug-resistant tuberculosis in Lisbon, Portugal: a molecular epidemiological perspective.葡萄牙里斯本的耐多药结核病：分子流行病学视角
Microb Drug Resist. 2008 Jun;14(2):133-43. doi: 10.1089/mdr.2008.0798.
7
pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates from the southeast region of Brazil.巴西东南部地区耐吡嗪酰胺结核分枝杆菌临床分离株中的pncA基因突变
J Antimicrob Chemother. 2006 Nov;58(5):930-5. doi: 10.1093/jac/dkl363. Epub 2006 Sep 13.
8
pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates in Portugal.葡萄牙耐吡嗪酰胺结核分枝杆菌分离株中的pncA基因突变
Antimicrob Agents Chemother. 2004 Jul;48(7):2736-8. doi: 10.1128/AAC.48.7.2736-2738.2004.
9
Iron enhances the antituberculous activity of pyrazinamide.铁可增强吡嗪酰胺的抗结核活性。
J Antimicrob Chemother. 2004 Feb;53(2):192-6. doi: 10.1093/jac/dkh042. Epub 2004 Jan 16.
10
Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan.台湾地区结核分枝杆菌分离株中吡嗪酰胺活性与pncA基因突变的相关性
Antimicrob Agents Chemother. 2003 Nov;47(11):3672-3. doi: 10.1128/AAC.47.11.3672-3673.2003.